Edwards Lifesciences Reports Strong Q2 2026 Performance and Raises Full-Year Guidance
Edwards Lifesciences Corporation reported a strong second-quarter performance in fiscal year 2026, delivering 12.5% sales growth driven by its expanding structural heart portfolio. The company is transitioning from a TAVR-centric model to a multi-platform strategy that includes Transcatheter Mitral and Tricuspid Therapies (TMTT) as well as surgical solutions. The firm noted continued success in the U.S., with SAPIEN 3 Ultra RESILIA driving competitive gains due to its advanced tissue technology. TAVR growth reached 10.5%, supported by sustained clinical momentum and a competitor's exit from the market last year, while TMTT saw impressive 44.8% growth as PASCAL and EVOQUE scaled effectively. Edwards raised full-year sales guidance to between 10% and 11%, citing strong first-half performance but cautioning about challenging comparisons in the second half of the year. The company also highlighted upcoming milestones, including a finalized U.S. TAVR National Coverage Determination (NCD) expected in September and key trial results from PROGRESS later this year.
Topics: mitral/tricuspid repair sales guidance structural heart TAVR growth